pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

831 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT783Endpoints585BioPharma Dive224onclive165BioSpace59Fierce Biotech57raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Flagship startup Serif says it has solved non-viral gene therapy in monkeys
    BOSTON — Serif Biomedicines, a startup launched last month by Flagship Pioneering, believes it has solved two technical challenges that have long prevented gene therapy from being delivered without…
    Endpoints · 2mo ago↗ source
  • Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
    It's becoming Hengrui Pharma's world, and some Western drugmakers are just living in it. China's largest pharma company, which boasts one of the biggest pipelines in the industry, has lined up Br…
    Endpoints · 2mo ago↗ source
  • <![CDATA[Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL]]>
    <![CDATA[Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.]]>
← prev
page 25 of 34
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago
↗ source
  • <![CDATA[Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma]]>
    <![CDATA[Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.]]>
    onclive · 2mo ago↗ source
  • Optum Rx unveils pharmacy model with clear fees, building on transparency push
    UnitedHealth Group’s Optum Rx on Monday unveiled a new approach to prescription drug benefits that it said offers its customers transparency into the entire drug supply chain. Under the new model…
    Endpoints · 2mo ago↗ source
  • <![CDATA[Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL]]>
    <![CDATA[Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.]]>
    onclive · 2mo ago↗ source
  • Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape
    It seems there’s room for two in the MASH market. When Novo Nordisk’s blockbuster weight loss drug Wegovy won approval in August 2025 to treat the fatty liver disease, some investors thought it w…
    Endpoints · 2mo ago↗ source
  • <![CDATA[MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors]]>
    <![CDATA[Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC]]>
    <![CDATA[First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.]]>
    onclive · 2mo ago↗ source
  • Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push
    Daiichi Sankyo is betting on its oncology franchise to push it past 3 trillion Japanese yen ($19 billion) in 2030 revenues. The drugmaker published a new five-year business plan on Monday ...
    Endpoints · 2mo ago↗ source
  • New home for Novo's Parkinson's cell therapy; GSK's deal to sell drug in China
    Plus, label expansions for two drugs targeting rare diseases, and Genmab scraps a Phase 1 cancer trial: 🧠 Novo's Parkinson's cell therapy finds a biotech home: Novo Nordisk has found a home for…
    Endpoints · 2mo ago↗ source
  • Inhibrx says combo therapy shrank more tumors than Merck's Keytruda alone
    San Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer. The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank more…
    Endpoints · 2mo ago↗ source
  • <![CDATA[Treatment Intensification Gains Momentum in mCSPC Management]]>
    <![CDATA[During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations]]>
    <![CDATA[Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.]]>
    onclive · 2mo ago↗ source
  • Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical win
    Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics rec…
    Endpoints · 2mo ago↗ source
  • <![CDATA[Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT]]>
    <![CDATA[R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selection]]>
    <![CDATA[In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss how real-world patient factors influence first-line treatment decisions in renal cell carcinoma. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Expanding ctDNA Applications to RCC and Germ Cell Tumors]]>
    <![CDATA[Experts explain how ctDNA tracking in metastatic cancer guides therapy tweaks, flags relapse early, and where it fails in brain/peritoneal disease.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice]]>
    <![CDATA[Learn how clinicians weigh symptoms, MRI changes and family goals to decide when a child’s tumor needs treatment—beyond simple size cutoffs.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[ctDNA in Metastatic Urothelial Carcinoma]]>
    <![CDATA[Experts explain how ctDNA tracking in metastatic cancer helps tailor immunotherapy, spot relapse early, and guide dose breaks—plus key limitations.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Institutional Perspectives on Treatment Thresholds in PLGG]]>
    <![CDATA[Experts weigh PLGG treatment choices, balancing chemo and MEK inhibitors, guided by vision decline, symptoms, tumor growth, and family logistics.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groups]]>
    <![CDATA[In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how clinicians approach treatment selection in renal cell carcinoma across diffe…
    onclive · 2mo ago↗ source
  • European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapy
    Drug developers are racing to make gene therapies that could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a company based just outside of Boston is poised to becom…
    Endpoints · 2mo ago↗ source
  • CSL sinks to nine-year low on revenue warning, $5B write-down
    CSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by about 4% and said it would have to take a new $5 billion impairment charge. The ...
    Endpoints · 2mo ago↗ source
  • <![CDATA[Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer]]>
    <![CDATA[The regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.]]>
    onclive · 2mo ago↗ source